Results 2025
Category: TG6002
Colorectal Cancer Hepatic Metastasis Modeling by Advanced 3D Bioprinting Allows Demonstration of Oncolytic Viral Chemotherapeutic Delivery
P. Erbs, et al. Cancers 2025 Abstract available on the MDPI website – Download the article
Contribution of yeast to synthetic virology
C. Rey, et al. Virologie 2025 Read the article on the JLE website – Download the article
TG6002 oncolytic vaccinia virusand chemotherapy synergy: apromising strategy for pancreaticductal adenocarcinoma
J. Foloppe, et al. Frontiers in Microbiology Septembre 2025 – Download the Article
A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
E. J. West et al.Clinical Cancer Research April 2025Download the publication herePublication
Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
Transgene to present multiple posters highlighting the potential of its exciting immunotherapy pipeline at AACR2023 15
Transgene announces Financial Calendar for 2023
Transgene announces Financial Calendar for 2023 15
R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
TRANSGENE R&D DAY
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
2Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administrationin patients with advanced gastrointestinal carcinomas
V. Moreno, et al. ESMO 2022 – Download the Poster